Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

Company Overview

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $2.35 to $2.55
• 50-Day Range: $2.05 to $5.60
• 52-Week Range: $1.78 to $10.14
• Volume: 42,163 shs
• Average Volume: 271,468 shs
• Market Capitalization: $50.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.40
• Consensus Rating: Moderate Buy

Adverum Biotechnologies Stock Analysis - MarketRank™

Adverum Biotechnologies scored higher than 76% of companies evaluated by MarketBeat, and ranked 231st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adverum Biotechnologies has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adverum Biotechnologies is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adverum Biotechnologies is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adverum Biotechnologies has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.67% of the float of Adverum Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adverum Biotechnologies has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Adverum Biotechnologies has recently increased by 3.50%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adverum Biotechnologies does not currently pay a dividend.

Dividend Growth

Adverum Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

10.67% of the float of Adverum Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adverum Biotechnologies has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Adverum Biotechnologies has recently increased by 3.50%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.06

News Sentiment

Adverum Biotechnologies has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Adverum Biotechnologies this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for ADVM on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Adverum Biotechnologies insiders have bought 3,216.83% more of their company's stock than they have sold. Specifically, they have bought $863,040.00 in company stock and sold $26,020.00 in company stock.

Percentage Held by Insiders

Only 4.20% of the stock of Adverum Biotechnologies is held by insiders.

Percentage Held by Institutions

48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADVM Stock Analysis - Frequently Asked Questions

How have ADVM shares performed this year?

Adverum Biotechnologies' stock was trading at $4.67 at the beginning of the year. Since then, ADVM shares have decreased by 48.0% and is now trading at $2.4290.
View the best growth stocks for 2025 here.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) issued its quarterly earnings data on Tuesday, April, 15th. The biotechnology company reported ($1.96) earnings per share for the quarter, missing analysts' consensus estimates of ($1.34) by $0.62.

When did Adverum Biotechnologies' stock split?

Adverum Biotechnologies's stock reverse split on Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Adverum Biotechnologies' major shareholders?

Top institutional shareholders of Adverum Biotechnologies include BML Capital Management LLC (13.13%), Principia Wealth Advisory LLC (8.16%), Goldman Sachs Group Inc. (2.21%) and Pale Fire Capital SE (1.76%). Insiders that own company stock include Braden Michael Leonard, Laurent Fischer, Peter Soparkar, Setareh Seyedkazemi, Brigit Riley, James Paul Scopa and Richard Beckman.
View institutional ownership trends.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 4/15/2025
• Today: 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADVM
• CIK: 1501756
• Web: www.adverum.com
• Phone: (650) 656-9323
• Fax: 650-329-8151
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $26.40
• High Stock Price Target: $40.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +956.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-117,170,000.00
• Net Margins: N/A
• Pretax Margin: -9,524.40%
• Return on Equity: -65.14%
• Return on Assets: -40.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.82
• Quick Ratio: 5.82

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 52.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.26 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 20,891,000
• Free Float: 19,928,000
• Market Cap: $52.23 million
• Optionable: Optionable
• Beta: 1.03